Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Iberdomide, Daratumumab and Dexamethasone VS Daratumumab, Bortezomib, and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma EXCALIBER

What's the purpose of this trial?

The goal of this clinical trial is to find the optimal dose of investigational drug iberdomide in combination with daratumumab and dexamethasone, and to study whether investigational drug iberdomide works in treating relapsed or refractory multiple myeloma when combined with daratumumab and dexamethasone.  

This trial is currently open and accepting patients.

What will happen during the trial?

Participants in this stage will be randomly assigned into one of four groups. Three of the groups will receive different doses of investigational drug Iberdomide in combination with Daratumumab and Dexamethasone. One group will receive comparator combination of Daratumumab, Bortezomib, and Dexamethasone. The three Iberdomide groups will receive different doses of investigational drug Iberdomide.

Participants in this stage will be randomized into one of two groups. Group A will receive investigational drug Iberdomide (at the dose selected by stage 1), Daratumumab, and Dexamethasone. Group B will receive the comparator combination of Daratumumab, Bortezomib, and Dexamethasone. 

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.

  • have measurable disease as defined by the trial criteria.
  • have received one to two prior lines of anti-myeloma therapy.
  • have achieved a partial response or better to at least one prior anti-myeloma regimen.
  • have not previously received treatment with a CD-38 directed therapy (for Stage 1 participants). For Stage 2 participants, previous CD-38 therapy is allowed if while receiving it you:
    • achieved at least a partial response,
    • your myeloma did not progress while receiving it, 
    • and your last dose of Daratumumab was more than three months prior to joining the study.
  • Previous treatment with Bortezomib is allowed as long as you:
    • achieved at least a minimal response, and 
    • you did not progress while receiving Bortezomib or within 60 days of your last dose.
  • do not have central nervous system involvement of your myeloma.
  • have not previously received treatment with investigational drug Iberdomide.
  • have not previously received an allogeneic stem cell transplant, and have not received an autologous stem cell transplant in the last three months.
  • have adequate bone marrow, liver, cardiac and lung function as described in the trial criteria.

Additional eligibility criteria apply and can be explained by the study doctor. 

Additional Trial Information

Phase 3

Enrollment: 864 patients (estimated)

View More

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.


Genesis Cancer and Blood Institute American Oncology Partners

Hot Springs, AR

Open and Accepting


Yale Cancer Center Smilow Cancer Hospital at Yale-New Haven

New Haven, CT

Open and Accepting


Florida Cancer Specialists South

Fort Myers, FL

Open and Accepting

Florida Cancer Specialists North

St. Petersburg, FL

Open and Accepting

Florida Cancer Specialists (West Palm Beach) West Palm Beach

West Palm Beach, FL

Open and Accepting


Winship Cancer Institute of Emory University

Atlanta, GA

Not Yet Accepting


Hematology Oncology Clinic

Baton Rouge, LA

Open and Accepting



Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting

University of Massachusetts Medical School

Worcester, MA

Open and Accepting


HCA Midwest Health

Kansas City, MO

Open and Accepting

New Jersey

Summit Health

Florham Park, NJ

Open and Accepting

North Carolina

Duke Cancer Center Duke University Medical Center

Durham, NC

Not Yet Accepting


TriHealth Bethesda North Hospital

Cincinnati, OH

Open and Accepting

Cleveland Clinic Taussig Cancer Institute

Cleveland, OH

Not Yet Accepting

MetroHealth Medical Center

Cleveland, OH

Not Yet Accepting

OhioHealth Grant Medical Center

Columbus, OH

Not Yet Accepting


Tennessee Oncology Memorial Plaza

Chattanooga, TN

Open and Accepting

Tennessee Oncology Centennial Clinic

Nashville, TN

Open and Accepting


UW Carbone Cancer Center University of Wisconsin Health

Madison, WI

Open and Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message

SparkCures Verified

SparkCures is working closely with Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.

Learn more about how we work with trial sponsors